Prostaglandins and other lipid mediators in Alzheimer's disease.
about
Role of redox signaling in neuroinflammation and neurodegenerative diseasesRapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution.Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse modelsRat brain docosahexaenoic acid metabolism is not altered by a 6-day intracerebral ventricular infusion of bacterial lipopolysaccharide.Coordination of gene expression of arachidonic and docosahexaenoic acid cascade enzymes during human brain development and aging.Microarray analysis on human neuroblastoma cells exposed to aluminum, β(1-42)-amyloid or the β(1-42)-amyloid aluminum complex.Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseasesIdentification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.Cyclooxygenase-2 inhibitor blocks the production of West Nile virus-induced neuroinflammatory markers in astrocytes.Alzheimer's disease and age-related memory decline (preclinical)Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosisInhibition of secreted phospholipase A2 by neuron survival and anti-inflammatory peptide CHEC-9Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia.LC/MS/MS method for analysis of E₂ series prostaglandins and isoprostanes.PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease.Relation of blood cadmium, lead, and mercury levels to biomarkers of lipid peroxidation in premenopausal women.Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic studyA fast one-step extraction and UPLC-MS/MS analysis for E2/D 2 series prostaglandins and isoprostanesThe fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation.Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET.The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.Neurodegeneration and inflammation.Prostaglandin transporter expression in mouse brain during development and in response to hypoxia.Intracellular- and extracellular-derived Ca(2+) influence phospholipase A(2)-mediated fatty acid release from brain phospholipids.Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease.Phospholipase A2 and arachidonic acid in Alzheimer's diseaseMicroRNAs in the brain: it's regulatory role in neuroinflammation.Positive and negative effects of prostaglandins in Alzheimer's disease.Alteration in the activation state of new inflammation-associated targets by phospholipase A2-activating protein (PLAA)Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease.Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity.Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A2 in a spatial-specific manner.Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia.Phospholipase A2-activating protein is associated with a novel form of leukoencephalopathy.Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures.Membrane Aging as the Real Culprit of Alzheimer's Disease: Modification of a Hypothesis.Exosomal biomarkers in Down syndrome and Alzheimer's disease.Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A2.Cross-talk between human mesenchymal stem/progenitor cells (MSCs) and rat hippocampal slices in LPS-stimulated cocultures: the MSCs are activated to secrete prostaglandin E2.Association between the characteristics of metabolic syndrome and Alzheimer's disease.
P2860
Q27012569-748FD70E-870D-41E6-A39A-20A7E434290BQ30486807-6B8D77E8-3AFD-4056-9D21-104FBB681AACQ30499792-80E736FF-DB2E-41D2-8D25-FA7DF503728BQ33689487-967A8703-8791-43A5-8E5B-3F466E339E69Q33806815-3C228178-22C2-4310-AFAB-066F7C6390BCQ33813237-2C77DD32-091E-44C9-AF7C-D4BABBAA68D8Q34071942-0889E0A8-3AA1-4668-8237-2CBAE9382672Q34735142-DF2E9CE1-DC81-4311-9F68-2C390DB4F340Q34840113-95D49F64-4E00-4F50-9476-206654773D15Q35041190-EC5546DA-FC39-4DDF-B3DF-08614CD5A280Q35070143-723B00EC-3A4C-41E4-8E72-5CFA242A73E9Q35110642-7B4C02CC-EB13-42F6-A70C-E25F31D75940Q35274780-C503B5B7-9B14-4F02-9644-E51F0BCEF0B7Q35771195-CFB3C40D-6AD5-4D03-8F3F-01303E48190FQ35823015-8E33B0F4-B8AA-4A30-A022-1C24337C1403Q35883537-BFA95F67-51CB-4187-8ED1-C5421D6D4111Q36316280-71A4F53D-CEB0-4522-A323-D9A8451865C2Q36718279-C258AB43-45E6-495A-9CA1-2C3E0F217196Q36806227-E5D02877-9127-4216-ABD3-D75E5A66EDA4Q36983897-165E3D56-C29F-432A-9441-C23D178E173FQ37054938-08AE29C4-7444-44B7-9A6C-2CFFE7946C4AQ37060101-508A2A72-10D0-4EC5-83AE-D9E117E9DBE2Q37141458-E281DAAC-6343-40E5-9969-F6DBC336C50FQ37328073-3519CF9B-DD14-4B2F-8710-81D4B3040C5AQ37701322-2FE9F060-2D73-4CC1-9F9E-18DC5FDEFB0FQ37765687-0983EA29-EB62-470B-B883-01A05B9B0447Q38073708-63FA529B-59FF-44AD-848E-6F503A9771F8Q38132922-5D1F9520-D1DE-44FF-9236-515DDB4C1955Q38293331-67892234-4882-42A4-AA9C-533DBB1473C5Q40343183-BED3A2BF-26D1-42F2-BA67-929CE7A5048CQ40631665-57E6C675-0F86-4C01-A2CF-7EEE38AB08C4Q41149645-05C10AED-7185-4BBF-B9D6-DCE613CC3759Q41864750-5229737D-D855-4D1B-A78E-8358F9CCC963Q41921317-A6AE7565-D921-47E4-A552-CA6B02CB878DQ44814173-CF6558A7-A17E-464C-B829-28A300D2CB28Q47949218-E7524CAB-F937-422E-ACA5-4F3646305671Q47960190-7F1B377A-9070-4187-A906-E1CB1F9D3EBAQ48143750-9DA85968-4D9E-4DFD-A6DA-8FC814DBABFEQ48874383-D628A0DB-9297-4FF9-849D-5EAEB47C19FCQ51018894-84822F5A-9EE3-4AE9-8BCE-849C55EF4DA0
P2860
Prostaglandins and other lipid mediators in Alzheimer's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prostaglandins and other lipid mediators in Alzheimer's disease.
@ast
Prostaglandins and other lipid mediators in Alzheimer's disease.
@en
Prostaglandins and other lipid mediators in Alzheimer's disease.
@nl
type
label
Prostaglandins and other lipid mediators in Alzheimer's disease.
@ast
Prostaglandins and other lipid mediators in Alzheimer's disease.
@en
Prostaglandins and other lipid mediators in Alzheimer's disease.
@nl
prefLabel
Prostaglandins and other lipid mediators in Alzheimer's disease.
@ast
Prostaglandins and other lipid mediators in Alzheimer's disease.
@en
Prostaglandins and other lipid mediators in Alzheimer's disease.
@nl
P2093
P1476
Prostaglandins and other lipid mediators in Alzheimer's disease.
@en
P2093
Nicolas G Bazan
Vittorio Colangelo
Walter J Lukiw
P304
P356
10.1016/S0090-6980(02)00031-X
P577
2002-08-01T00:00:00Z